![]() NXY-059 structure
|
Common Name | NXY-059 | ||
---|---|---|---|---|
CAS Number | 168021-79-2 | Molecular Weight | 381.333 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C11H13NNa2O7S2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of NXY-059Disufenton sodium (NXY-059) is the disulfonyl derivative of the neuroprotective spin trap phenylbutynitrone(PBN), both NXY-059, its parent PBN and their hydrolysis/oxidation product MNT are very powerful scavengers of free radicals. IC50 value:Target: Neuroprotectantin vitro: Disufenton sodium is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN) [1]. In an in vitro blood-brain barrier (BBB) model, 250 mM of Disufenton sodium administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by Disufenton sodium [2]. in vivo: Disufenton sodium reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for Disufenton sodium and 1.4 mg/kg for PBN), Disufenton sodium is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for Disufenton sodium is 3 to 6 hours after the start of recirculation [1]. Disufenton sodium, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. Disufenton sodium treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter [3]. |
Name | Disufenton sodium |
---|---|
Synonym | More Synonyms |
Description | Disufenton sodium (NXY-059) is the disulfonyl derivative of the neuroprotective spin trap phenylbutynitrone(PBN), both NXY-059, its parent PBN and their hydrolysis/oxidation product MNT are very powerful scavengers of free radicals. IC50 value:Target: Neuroprotectantin vitro: Disufenton sodium is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN) [1]. In an in vitro blood-brain barrier (BBB) model, 250 mM of Disufenton sodium administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by Disufenton sodium [2]. in vivo: Disufenton sodium reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for Disufenton sodium and 1.4 mg/kg for PBN), Disufenton sodium is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for Disufenton sodium is 3 to 6 hours after the start of recirculation [1]. Disufenton sodium, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. Disufenton sodium treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter [3]. |
---|---|
Related Catalog | |
References |
Molecular Formula | C11H13NNa2O7S2 |
---|---|
Molecular Weight | 381.333 |
Exact Mass | 380.992889 |
PSA | 159.91000 |
LogP | 2.90730 |
Storage condition | -20°C |
Hazard Codes | Xi |
---|
Cerovive |
UNII:7M1J3HN9VO |
1,3-Benzenedisulfonic acid, 4-[[(1,1-dimethylethyl)oxidoazanylidene]methyl]-, sodium salt (1:2) |
Disodium (tert-butylimino)methyl)benzene-1,3-disulfonate N-oxide |
Disodium 4-{[(2-methyl-2-propanyl)(oxido)-λ-azanylidene]methyl}-1,3-benzenedisulfonate |
CPI 22 |
Disufenton sodium |
Sodium (Z)-4-((tert-butyloxidoimino)methyl)benzene-1,3-disulfonate |
NXY-059 |
Disodium,4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate |